(+/-)-4-Hydroxy Mephenytoin
(+/-)-4-Hydroxy Mephenytoin structure
|
Common Name | (+/-)-4-Hydroxy Mephenytoin | ||
|---|---|---|---|---|
| CAS Number | 61837-65-8 | Molecular Weight | 234.251 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H14N2O3 | Melting Point | 153-154ºC | |
| MSDS | Chinese USA | Flash Point | 48.2 °F | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
Use of (+/-)-4-Hydroxy Mephenytoin4-Hydroxymephenytoin is a metabolism of an antiepileptic drug mephenytoin, which is used as a CYP2C19 substrate. |
| Name | (+/-)-4-Hydroxy Mephenytoin |
|---|---|
| Synonym | More Synonyms |
| Description | 4-Hydroxymephenytoin is a metabolism of an antiepileptic drug mephenytoin, which is used as a CYP2C19 substrate. |
|---|---|
| Related Catalog | |
| In Vitro | 4-Hydroxymephenytoin is a metabolism of mephenytoin, which is an antiepileptic drug, and used as a CYP2C19 substrate[1]. 4-Hydroxymephenytoin (4'-Hydroxymephenytoin) is used for developing UltraPerformance LC (UPLC) tandem mass spectrometry assays for evaluating CYP probe drugs and their relevant metabolites in human urine or plasma samples[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Melting Point | 153-154ºC |
| Molecular Formula | C12H14N2O3 |
| Molecular Weight | 234.251 |
| Exact Mass | 234.100449 |
| PSA | 69.64000 |
| LogP | 0.66 |
| Index of Refraction | 1.568 |
| Storage condition | 2-8℃ |
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol |
| Flash Point(F) | 48.2 °F |
| Flash Point(C) | 9 °C |
|
The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet.
Biochem. Pharmacol. 93(3) , 389-400, (2015) There is an unmet medical need for novel NAFLD treatments. Here we have examined the effects of liver-selective NO donor (V-PYRRO/NO) as compared with metformin on hepatic steatosis and glucose tolera... |
|
|
Size- and time-dependent alteration in metabolic activities of human hepatic cytochrome P450 isozymes by gold nanoparticles via microsomal coincubations.
Nanoscale Res. Lett. 9(1) , 642, (2014) Nano-sized particles are known to interfere with drug-metabolizing cytochrome P450 (CYP) enzymes, which can be anticipated to be a potential source of unintended adverse reactions, but the mechanisms ... |
|
|
Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method.
Rapid Commun. Mass Spectrom. 18(15) , 1675-80, (2004) A reliable and easy to use liquid chromatography/tandem mass spectrometry (LC/MS/MS) method without the use of sample extraction was developed for the simultaneous quantification of urinary concentrat... |
| 4-hydroxy mephenytoin |
| 5-Ethyl-5-(4-hydroxyphenyl)-3-methyl-2,4-imidazolidinedione |
| 5-Ethyl-5-(4-hydroxyphenyl)-3-methylimidazolidine-2,4-dione |
| 2,4-Imidazolidinedione, 5-ethyl-5-(4-hydroxyphenyl)-3-methyl- |
| 4-Hydroxymephenytoin |